Lit­tle Mar­i­nus sees its shares eclipsed as the Sage ri­val fails to com­pare on PPD in PhII

The ex­ec­u­tive team at Sage $SAGE have skirt­ed an­oth­er po­ten­tial pit­fall on its way to rack­ing up a big fu­ture for its de­pres­sion drug Zul­res­so.

Lit­tle Mar­i­nus Phar­ma­ceu­ti­cals $MRNS had sought to chal­lenge the Sage drug with an IV for­mu­la­tion — fol­lowed by an oral ver­sion — of ganax­olone for post­par­tum de­pres­sion. But re­searchers say their Phase II study failed to pos­i­tive­ly dif­fer­en­ti­ate it­self from a place­bo at 28 days — leav­ing them to hold up “clin­i­cal­ly mean­ing­ful” da­ta with­in the first day of ad­min­is­tra­tion com­pared to the con­trol arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.